MELACCIO, ASSUNTA
 Distribuzione geografica
Continente #
NA - Nord America 956
EU - Europa 374
AS - Asia 104
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.435
Nazione #
US - Stati Uniti d'America 956
IT - Italia 105
SE - Svezia 104
DE - Germania 75
CN - Cina 74
GB - Regno Unito 25
FR - Francia 20
CZ - Repubblica Ceca 16
BE - Belgio 10
FI - Finlandia 9
IN - India 9
VN - Vietnam 9
SG - Singapore 5
KR - Corea 4
IE - Irlanda 3
IR - Iran 3
UA - Ucraina 2
CH - Svizzera 1
EU - Europa 1
LU - Lussemburgo 1
RS - Serbia 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.435
Città #
Chandler 146
Fairfield 101
Woodbridge 95
Nyköping 88
Ashburn 81
Ann Arbor 57
Bari 56
Seattle 55
Cambridge 52
Houston 51
Wilmington 35
New York 28
Lawrence 25
Roxbury 22
Beijing 19
Brno 15
Des Moines 15
Nanjing 15
Leawood 13
Marseille 13
Rome 13
Inglewood 11
Brussels 10
Dearborn 10
Jacksonville 10
Princeton 10
Dong Ket 9
San Diego 9
Brooklyn 7
Boardman 6
London 6
Munich 6
Nanchang 5
Nürnberg 5
Paris 5
Singapore 4
Ardabil 3
Dublin 3
Guangzhou 3
Helsinki 3
Jiaxing 3
Los Angeles 3
Redwood City 3
Santa Marinella 3
Suri 3
Tianjin 3
Acton 2
Fano 2
Grafing 2
Hebei 2
Jinan 2
Kilburn 2
Kunming 2
Landshut 2
Milan 2
Pune 2
San Francisco 2
Shenyang 2
Washington 2
Augusta 1
Baotou 1
Bratislava 1
Brescia 1
Chengdu 1
Chicago 1
Edinburgh 1
Genova 1
Gurgaon 1
Hefei 1
Imbersago 1
Islington 1
Jinhua 1
Kyiv 1
Luxembourg 1
Modugno 1
Mumbai 1
New Bedfont 1
New Delhi 1
Norwalk 1
Olomouc 1
Redmond 1
Richmond 1
Rovato 1
San Mateo 1
Sankt Augustin 1
Shanghai 1
Shaoxing 1
Shenzhen 1
Southwark 1
Stimigliano 1
Tettnang 1
Wuhan 1
Wuxi 1
Xian 1
Zhengzhou 1
Zurich 1
Totale 1.201
Nome #
Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival 220
Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies 110
Functional and biological role of endothelial precursor cells in tumour progression: A new potential therapeutic target in haematological malignancies 105
null 101
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment 100
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression 62
Angiogenesis and Antiangiogenesis in Multiple Myeloma 56
Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study 52
Efficacy of filgrastim, lenograstim and peg-filgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative disorders. 49
Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers? 49
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients 48
Real-life experience with omalizumab in chronic spontaneous urticaria. 47
null 43
Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial 39
null 38
MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease 37
Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma 37
Prognostic and therapeutic role of angiogenic microenvironment in thyroid cancer 36
Myeloma cells regulate {miRNA} transfer from fibroblast-derived exosomes by expression of {lncRNAs} 32
The bone marrow niche landscape: a journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu 28
null 26
An atypical presentation of intestinal neuroendocrine tumor. 26
Telemedicine DSS-AI Multi Level Platform for Monoclonal Gammopathy Assistance 26
null 25
null 24
Thrombopoietin promotes angiogenesis and disease progression in patients with multiple myeloma 24
null 22
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma 22
Difficult therapeutic choices in a patient suffering from severe scleroderma and colon adenocarcinoma. 18
Savage therapy with rituximab in severe lupus nephritis. 17
Peculiar presentation of skin lymphoma could be missdiagnosed as sarcoidosis: a case report. 15
Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance 9
Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications 6
MicroRNAs-based nano-strategies as new therapeutic approach in multiple myeloma to overcome disease progression and drug resistance 6
Telemedicina applicata: il caso di studio di "Telemeliolab" 5
Multiple Myeloma: Risk Factors, Diagnosis and Treatments 2
Clinical and experimental evidences of anti-myeloma activities of zolendronic acid 2
Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma 1
Totale 1.565
Categoria #
all - tutte 8.167
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.167


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020239 25 6 8 12 16 23 31 29 28 16 29 16
2020/2021334 15 20 16 48 53 17 26 40 14 30 26 29
2021/2022258 24 10 5 19 14 17 9 17 23 19 38 63
2022/2023389 44 66 37 26 38 61 11 38 49 5 9 5
2023/2024189 11 26 5 15 20 49 10 11 0 2 2 38
2024/202510 10 0 0 0 0 0 0 0 0 0 0 0
Totale 1.565